Diadema Partners’s Cytokinetics CYTK Stock Holding History

Diadema Partners’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.2M	Buy	+200,000	New	+$12.7M	2.24%	10

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Diadema Partners's CYTK Position: Q2 2025 in Review

Diadema Partners sold out of Cytokinetics (CYTK) in Q2 2025, closing a stake of 20,000 shares — an estimated $804K sold.

Diadema Partners first reported a position in CYTK in Q1 2025 and held it in 1 quarter. The position peaked at $804K in Q1 2025. 311 funds tracked by Wall St. Rank hold CYTK as of Q2 2025.

Diadema Partners reported no remaining Cytokinetics position as of Q2 2025 after selling out during the quarter.
Diadema Partners sold 20,000 Cytokinetics shares in Q2 2025, an estimated $804K.
Diadema Partners first reported a position in Cytokinetics in Q1 2025 and held it in 1 quarter.
Diadema Partners's Cytokinetics position peaked at $804K in Q1 2025.
311 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2025.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.